merged_drug-prices-medicare.txt
<question_number>1</question_number>
<answer>The $2,000 annual cap on patient costs for drugs taken at home will go into effect next year, while the new negotiated prices will take effect in 2026.</answer>

<question_number>2</question_number>
<answer>The Project 2025 playbook suggests that if former President Donald J. Trump wins the White House in November, particularly with full Republican control of Congress, the drug price negotiation program could be repealed, which would impact the number of drugs negotiated by the federal government.</answer>

<question_number>3</question_number>
<answer>Vice President Kamala Harris cast the tiebreaking vote for the legislation that delivered the drug price negotiation program, and she has focused some of her early presidential campaign on the Biden administration's drug pricing reforms, including the cap on monthly insulin costs for Medicare recipients, indicating that efforts to "take on Big Pharma" are among her first priorities as president.</answer>

<question_number>4</question_number>
<answer>N/A</answer>

<question_number>5</question_number>
<answer>N/A</answer>

<question_number>6</question_number>
<answer>N/A</answer>

<question_number>7</question_number>
<answer>Imbruvica, with a negotiated price of $9,319, would require the most monthly refills before reaching the $2,000 annual cap.</answer>

<question_number>8</question_number>
<answer>The three most expensive medications (Enbrel, Imbruvica, and Stelara) have a total negotiated price of $16,369. The total negotiated price for all 10 drugs is $17,489. Therefore, the three most expensive medications represent 93.6% of the total negotiated price for all 10 drugs.</answer>

<question_number>9</question_number>
<answer>The difference in negotiated price between Jardiance ($197) and Farxiga ($178), which treat the same conditions, is $19.</answer>

<question_number>10</question_number>
<answer>The total negotiated price for all drugs produced by companies mentioned in relation to legal challenges to the program (Bristol Myers Squibb, Johnson & Johnson, and AbbVie) is $16,545.</answer>